Kornimate/medical-research-clean huggingface dataset:
depression and facial identity recognition abilities in patients with multiple sclerosis

Conditions: Multiple Sclerosis; Depression

Summary: cognitive and emotional disorders are often encountered in multiple sclerosis (ms) cases: depressive and bipolar disorders are twice as frequent as in general population. cognitive disorders, (particularly attention and dysexecutive disorders), appear in early stages of the disease's evolution, in cases of lightly or moderately disabled patients, with a recent evolution, with a "minor" form of the disease, even in clinically isolated syndromes (cis). emotional disturbances are essentially linked to mood disorders of depression-type. last ten years, emotional processing in multiple sclerosis cases was investigated in various trials, especially regarding the recognition of facial and emotional expressions. these studies reported data, supporting an impairment of the perception of emotion, particularly those with negative valence. the objective of this study is to investigate the link between recognition of facial and emotional expressions and depression in multiple sclerosis cases.


Eligibility criteria:
inclusion criteria: * man or woman between 18 and 65 years old * participant understanding and able to speak french * participant understanding the participant informed sheet and who has signed the informed consent * participant with health insurance ms patients : * patient with relapsing remitting multiple sclerosis form * expanded disability status scale (edss) \< 4 * patient without motor disorders, cerebellar or significant upper limb somatosensory or visual disturbances control participants : * participant without global cognitive deterioration exclusion criteria: * participant taking part of other biomedical studies involving drug tests * participant with other neurological pathologies, head trauma with loss of consciousness, psychiatric pathologies, serious general affections, alcoholism, perception disorders, dysarthria, disorders preventing oral communication and reading, under prescription of psychotropic drugs * mental or visual incapacity to take part in the study * participant with antecedents of drug or alcohol abuse * allergy to the components of the gel used during the eeg * patients with mri contraindications : pacemaker or neurostimulator or implantable cardioverter defibrillator (icd), cochlear implants, ocular or cerebral ferromagnetic foreign body close to the nerve structures, metal prostheses, * uncooperative or agitated patients, * claustrophobic patients, * ventricular peritoneal shunts and neurosurgical valves, * braces * ms patient without mri in the last 4 months * adults under guardianship, under judicial protection, persons deprived of liberty, * pregnant or breast feeding women, * ms patient with another ms form than relapsing-remitting, * ms patient who encountered a relapse in the last 6 weeks, * ms patient treated with corticoids in the last month.
comparison of rpl554 with placebo and salbutamol in asthmatic patients

Conditions: Asthma

Summary: the number of people with of asthma and allergy is still increasing and a large number of patients still do not have their asthma well controlled. there is therefore a need for new asthma treatments that work well and have less side effects. the study compares a new experimental drug rpl554 with a marketed asthma drug (salbutamol) and placebo.

a seven way crossover study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled rpl554 compared to salbutamol and placebo in patients with mild to moderate chronic asthma. salbutamol is a marketed beta-2 agonist typically used to treat bronchospasm (due to any cause, allergen asthma or exercise-induced), as well as chronic obstructive pulmonary disease but has associated dose-related systemic side effects. rpl554 is a dual pde3 and pde4 inhibitor that has bronchodilatory and anti-inflammatory actions and also the potential to stimulate increases in mucociliary clearance via its proven ability to activate cftr. four different doses of rpl554 will be compared with placebo and a two doses of salbutamol as benchmarks for bronchodilation and systemic side effects.

Eligibility criteria:
inclusion criteria: * provided written informed consent * males agree not to donate sperm and either be abstinent or use adequate contraception. females to be post-menopausal or surgically sterile * non-smoker or ex-smoker \>6 months * diagnosed asthma for at least 6 months * pre-bronchodilator fev1 ≥60% and ≤90% of predicted normal value and ≥1.5 l at screening * increase in fev1 of 15% within 30 minutes after a 2.5mg dose of nebulised salbutamol * systolic blood pressure 90 to 145 mmhg, diastolic blood pressure 50 to 90 mmhg and heart rate 45 to 80 beats per minute (bpm) after resting for 5 minutes in a supine position (average from two measurements) * capable of withdrawing from labas, lamas and samas before screening and during study and sabas before screening and for 8 hours before each dose exclusion criteria: * asthma exacerbation in the last 3 months * any prior life threatening episode of asthma (intensive care admission) * any clinically significant disease or disorder or clinically relevant screening result * qtcf interval \>450 ms or qt interval \>500 ms or other abnormality in ecg * history of ischemic heart disease or heart failure. history of recurrent or current clinically significant arrhythmia or ecg abnormality as judged by the investigator * treatment with systemic glucocorticosteroids within 30 days before screening * a suspected/manifested infection according to who risk classification 2, 3 or 4
waterjet versus ultrasound dissection during hepatic transection

Conditions: Liver Tumour

Summary: before liver transection patients are allocated to either waterjet or cusa to divide the liver parenchyma.

transection time, bloodloss, total operation time and postoperative complication rates are registered.

Eligibility criteria:
inclusion criteria: * hepatic tumour suitable for resection * patients 18 year or older segmental resection local resection left sided hemihepatectomy exclusion criteria: * right sided hemihepatectoyreresection in situ split liver extended left- and rightsided hemihepatectomy lobus caudatus resection central resections hilus tumour/klatskin/cholangiocarcinoma surgery on biliary tree extended resection on other organs resection on gallbladder resection on other organs during the same operation.

Keywords: liver transection bloodloss operation time safety feasibility
dental implant care and oral hygiene practices

Conditions: Peri-implant Mucositis; Peri-Implantitis; Dental Plaque

Summary: objective: this study investigated how patients' knowledge, attitude, and perceptions influence their oral hygiene practices as well as peri-implant health. materials and methods: participants with single implant crowns placed in 2007-2011 completed a questionnaire that examined their knowledge, attitude, and perceptions on oral hygiene practices and peri-implant health before receiving a periodontal examination, prophylaxis, and oral hygiene education. clinical parameters recorded were peri-implant probing depths and plaque index, width of keratinized mucosa, implant crown characteristics, reason for tooth loss, and diagnosis of peri-implant health.

first, a trained clinical research dental assistant interviewed the participants and showed them pictures of oral hygiene aids so that the participants could answer the survey questions accurately. subsequently, a periodontal examination, dental prophylaxis, and oral hygiene education were performed. participants with active diseases e.g. caries, periodontitis, or peri-implantitis were referred for further management. the following clinical parameters were recorded during the examination: 1. probing depths at 6 sites around the implant (mesiobuccal, midbuccal, distobuccal, distolingual, midlingual and mesiolingual) 2. plaque index (silness \& loe 1964) at 4 sites around the implant (mesial, buccal, distal and lingual) 3. amount of keratinized mucosa at the implant site 4. characteristics of the implant crown: * type of implant crown (screw- or cement-retained) and * position of crown margins (supra-, equi- or sub-gingival) 5. reason(s) for tooth loss 6. diagnosis of peri-implant health * normal * mucositis, defined as 3 or more bleeding points per implant * peri-implantitis, defined as implant thread exposure that was either clinically visible or detectable with a periodontal probe.

Eligibility criteria:
inclusion criteria: * english speaking patient * aged 21 years old or above * received at least 1 implant-supported single crown from nuh in the year 2007-2011 (in functional loading for at least 5 years) exclusion criteria: * implant is used to restore overdentures or multi-unit restorations such as splinted crowns, fixed partial dentures, and cantilevers. * pregnant/lactating women * parkinson's disease or any other debilitating diseases * physical or mental disabilities that may impair oral hygiene practices * poorly controlled diabetes * heavy smoker (10 or more cigarettes per day) * radiation therapy in head and neck region * hiv, tb, hepatitis or other infectious diseases * drug and alcohol abuse

Keywords: dental devices home care awareness peri-implant mucositis peri-implantitis
the impact of dancing in parkinson's disease

Conditions: Parkinson Disease

Summary: this clinical study intends to confirm the results of previous studies showing the positive effect of dance on patients with parkinson's disease on both mental and physical health via a randomized controlled trial. patients will be randomized into the intervention group (dance courses in addition to standard care) or in the control group (standard care).

this is a clinical study on the benefits of dance in parkinson's disease. in recent years, dance has become an interesting strategy to promote motor and non-motor functions in parkinson's disease. more than a rehabilitation strategy, dance appears to be an optimal approach to promote functional outcomes as it combines physical, rhythmic, cognitive, emotional and social elements that could have a positive impact on multiple impairments in parkinson's disease. the investigators believe that the notion of pleasure is crucial for rehabilitation, especially in people suffering from depression, and that it is often not taken into account in conventional rehabilitation strategies. the goal of the present study is to confirm these preliminary results. this clinical study will run over two years, from january 2022 to january 2024, but an experimental session will last 4 months. the aim of this protocol is to better characterize the impact of dance on well-being, disease progression and possible neuronal reorganization in patients with parkinson's disease. a better quality of life, a higher level of satisfaction and an improvement in functional status are expected in the experimental group. during this study, three examinations will be carried out over 4 months. one at the start of the study, one at mid-term (after 8 weeks) and one at the end of the study. these evaluations will take place at the place of the dance lessons for the experimental group and within the university hospital for the control group. assessment will be done through different scales and questionnaires to assess well-being, satisfaction, feelings of happiness, functional status, cognitive functions and the correlation between functional and cognitive progress and neuronal activity. this study is a "controlled and randomized" study that is to say that in a random manner, half of the participants will participate in weekly dance sessions lasting 60 minutes in addition to their conventional physiotherapy sessions while the control group will only receive conventional physiotherapy sessions during the first 4 months but will still benefit from dance sessions after the 4 months of evaluation.

Eligibility criteria:
inclusion criteria: * patient with parkinson's disease * hoehn \& yahr stadium \<3 * signature of the written consent form exclusion criteria: * no cardiac or respiratory or neurological or rheumatological disease incompatible with the practice of a physical activity * has not had any surgery interfering with motor function in the past 6 months * has no cognitive impairment - moca \<26 * does not present hearing problems that do not all
families expectations and hope raised by an evaluation of consciousness in patients in a vegetative state

Conditions: Disorders of Consciousness; Qualitative Research; Ethics; Neuroimaging

Summary: progress in resuscitation has increased the chances of survival after anoxic or traumatic brain injury. more and more patients with severe cerebral damages are resuscitated but upon awakening from coma, some patients remain in a state which cannot be qualified as conscious and is now known as an unresponsive wakefulness syndrome (uws; formerly known as vegetative state). this condition can be transitory and evolve towards recovery, or remain chronic and lasting for years. to improve the diagnosis of patients with disorders of consciousness, recent advances in brain imaging have led to the development of new methods of detecting awareness. in the absence of overt behavioral responses from these patients, imaging-based diagnostic methods have been first used to assess whether some cerebral areas were preserved in uws patients and showed an activation of the primary sensory cortices in some uws patients, whether it occurs at the auditory, visual or somatosensory level. unavoidable technical and ethical issues are raised for clinicians before responding to such requests: 1. is it technically possible to generalize neuroimaging protocols to all healthcare institutions? 2. is it ethically acceptable to propose neuroimaging protocols without an accurate estimation of their psychological impact on families and caregivers? the present study aims to understand and anticipate the technical and ethical issues related to an evaluation of consciousness with functional neuroimaging. how the evaluation of awareness in a patient affects the caregivers and family members will be investigated. by using qualitative research hopes and expectations will be clarified through the experiences of families, clinicians and nurses faced to this situation. will be included in this research professional caregivers and persons closely related to uws patients: * family members or close circle visiting the patients on a regular basis * referring clinicians * nurses in charge of the patients' care this prospective study uses qualitative, interview-based, research. two key-moments are explored in succession to examine the impact of a neuroimaging evaluation of consciousness in institutionalized uws patients: * interviews of professional caregivers and families about their hopes concerning the evaluation of consciousness of uws patients, * interviews of professional caregivers and families about the impact of evaluating consciousness on their beliefs


Eligibility criteria:
inclusion criteria: * adult family members, clinicians, nurses (aged \>18 years) closely related to uws patients * patients diagnosed as being in an uws exclusion criteria: * patients in a minimally conscious state, in a locked-in-syndrome of akinetic mutism * refusal of family members, clinicians or nurses to participate to the study * family members considered by clinicians not to be capable of passing the interviews * subjects aged \< 18 years * non french speaking subjects
hepasphere interventional therapy using digital subtraction angiography（dsa） for cervical carcinoma

Conditions: Cervical Carcinoma

Summary: the purpose of this study is to evaluate the safety and efficacy of hepasphere interventional therapy using digital subtraction angiography（dsa） for cervical carcinoma.

by enrolling patients with cervical carcinoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of hepasphere interventional therapy using digital subtraction angiography（dsa） for cervical carcinoma.

Eligibility criteria:
inclusion criteria: 1. age:18-80 2. karnofsky performance status \>60 3. diagnosis of cervical carcinoma based on histology or the current accepted radiological measures. 4. classification tumor,nodes,metastasis-classification(tnm) stage: ⅱ,ⅲ,ⅳ 5. will receive interventional therapy 6. life expectancy: greater than 3 months 7. patients' routine blood test, liver function and kidney function have no obvious abnormalities 8. ability to understand the study protocol and a willingness to sign a written informed consent document exclusion criteria: 1. patients with other primary tumor except cervical carcinoma 2. history of coagulation disorders or anemia

Keywords: cervical carcinoma hepasphere
the complete treatment of bifurcation with two-stent techniques: randomized comparison of crush versus culotte technique

Conditions: Coronary Artery Disease

Summary: in this complete randomized trial, using the contemporary second-generation drug-eluting stent, we aimed to test whether the crush technique is superior to the culotte technique for the treatment of bifurcation lesions in terms of 1-year target-lesion failure.


Eligibility criteria:
inclusion criteria: 1. age ≥19 years 2. de novo coronary lesions eligible for drug-eluting stent implantation 3. medina 1,1,1 or 1,0,1 or 0,1,1 de novo bifurcation lesions (lm or non-lm) and those of main vessel or side branch can be covered by 2 stents 4. reference vessel diameter of side branch ≥2.5 mm by visual estimation exclusion criteria 1. current or potential pregnancy 2. inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator 3. subjects with st elevation myocardial infarction \<24 h from the onset of chest pain 4. cardiogenic shock
a study of adx-102 in subjects with allergic conjunctivitis

Conditions: Conjunctivitis, Allergic

Summary: a multi-center, double-masked, randomized, vehicle-controlled, phase 2b evaluation of the onset and duration of adx-102 ophthalmic drops (0.5% and 0.1%) compared to vehicle of adx-102 ophthalmic drops in the conjunctival allergen challenge (ora-cac®) model of acute allergic conjunctivitis.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age of either gender and any race * have a positive history of ocular allergies and a positive skin test reaction to a seasonal (grasses, ragweed, and/or trees) or perennial allergen (cat dander, dog dander, dust mites, cockroach) as confirmed by an allergic skin test within the past 24 months * have a calculated visual acuity of 0.7 logmar or better in each eye as measured using an etdrs chart exclusion criteria: * have known contraindications or sensitivities to the use of the investigational product or any of its components * have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters (including but not limited to narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium or a diagnosis of dry eye) * have had ocular surgical intervention within three (3) months prior to visit 1 or during the study and/or a history of refractive surgery within the past six (6) months * have a known history of retinal detachment, diabetic retinopathy, or active retinal disease * have the presence of an active ocular infection (bacterial, viral or fungal) or positive history of an ocular herpetic infection at any visit * be a female who is currently pregnant, planning a pregnancy, lactating, not using a medically acceptable form of birth control throughout the study duration and for 14 days prior to the installation of investigational product, or has a positive urine pregnancy test at visit 1

Keywords: adx-102 allergic conjunctivitis
magnetic resonance imaging study of jm-4 in multiple sclerosis/clinically patients

Conditions: Multiple Sclerosis

Summary: this is a phase 0/1 study of ms patients to determine the safety and potential efficacy of a novel, small human peptide designated as jm-4. the study will involve treatment for 5-7 days with jm-4 to determine the effects of gadolinium(+) lesion number and volume in the brains of patients.

this study is the first study of jm-4 in patients with multiple sclerosis and is intended to show safety and potential efficacy in changing the size and/or number of gad(+) lesions in the brain. the initial dose level of 1 mg/kg/ will establish safety of jm-4 treatment after 5-7 days of treatment via intravenous infusion over 30 minutes daily in3-5 patients with multiple sclerosis. mri examinations will be conducted prior to treatment with jm-4 and 8 days after the initiation of treatment for the purpose of quantitating gad(+) brain lesions. once initial safety is established, the next group of 3-5 patients will receive 4 mg/kg/ of jm-4 daily for 5-7 days via 30 minute intravenous infusions, with mri scans conducted prior to treatment and 8 days after the initial dose of jm-4. once safety is established in this cohort of patients, a third group of patients may receive 9 mg/kg/ of jm-4 daily for 5-7 days via 30 minute infusions, with mri scans conducted prior to the initial treatment and 8 days after the initial treatment.

Eligibility criteria:
inclusion criteria: * definite ms (mcdonald criteria) or cis * gad(+) mri brain lesion on screening exam, with or without clinical activity followed by a baseline mri * edss of 0-5.5 inclusive * weight of 40-115 kg * females must be post-menopausal or surgically sterilized or use a hormonal contraceptive, intra-uterine device or diaphragm with spermicide during the study * not be pregnant or breast feeding * males must be willing to use contraception during each day of the study * be willing to comply with study procedures and protocols for the duration of the study * voluntarily provide informed consent * be wiling and physically able to attend the study center as required for all study screening and procedures exclusion criteria: * taking tysabri, gilenya, tecfidera, aubagio, ocrevus or other immunosuppressive drugs within the prior 3 months * received mitoxantrone or lemtrada at any time * consumption of corticosteroids within the past 30 days * current or less than 5 years prior malignancy (excluding basal cell or squamous cell skin cancer) * serious systemic disorder which might, in the opinion of the investigators, interfere with safety, compliance, treatment or evaluation of efficacy. conditions would include but not be limited to significant cardiac, liver, kidney, lung or cerebrovascular disease, hiv, serious infections, serous psychiatric disease or poorly controlled diabetes mellitus * aversion, intolerance or allergy to repeated mri with gadolinium administration